{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:13Z","timestamp":1792292593650,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01345-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:02:26Z","timestamp":1775656946000},"page":"1525-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multicenter Real-World Outpatient Use of Intravenous Omadacycline"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-096X","authenticated-orcid":false,"given":"Lucinda J.","family":"Van Anglen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy L.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58:1279\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/cid\/ciz242","volume":"69","author":"RR Watkins","year":"2019","unstructured":"Watkins RR, Deresinski S. Omadacycline: a novel tetracycline derivative with oral and intravenous formulations. Clin Infect Dis. 2019;69:890\u20136.","journal-title":"Clin Infect Dis"},{"key":"1345_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528\u201338.","journal-title":"N Engl J Med"},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:1080\u201390.","journal-title":"Lancet Infect Dis"},{"key":"1345_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517\u201327.","journal-title":"N Engl J Med"},{"key":"1345_CR6","unstructured":"NUZYRA\u00ae (omadacycline) [package insert]. Paratek Pharmaceuticals, Inc. Boston, MA: 2018."},{"key":"1345_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01087-24","volume":"69","author":"TM File Jr","year":"2025","unstructured":"File TM Jr, Ramirez JA, Wilde AM. New perspectives on antimicrobial agents: omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus). Antimicrob Agents Chemother. 2025;69:e0108724.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR8","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/phar.2185","volume":"38","author":"KE Barber","year":"2018","unstructured":"Barber KE, Bell AM, Wingler MJB, et al. Omadacycline enters the ring: a new antimicrobial contender. Pharmacotherapy. 2018;38:1194\u2013204.","journal-title":"Pharmacotherapy"},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/IDR.S171352","volume":"12","author":"RM Burgos","year":"2019","unstructured":"Burgos RM, Rodvold KA. Omadacycline: a novel aminomethylcycline. Infect Drug Resist. 2019;12:1895\u2013915.","journal-title":"Infect Drug Resist"},{"key":"1345_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58:1127\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334.","journal-title":"Future Microbiol"},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24:6409\u201319.","journal-title":"Bioorg Med Chem"},{"key":"1345_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17","volume":"62","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2018;62:e02327-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19","volume":"64","author":"MA Pfaller","year":"2020","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64:e02488-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-18","volume":"63","author":"C Shoen","year":"2019","unstructured":"Shoen C, Benaroch D, Sklaney M, Cynamon M. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;63:e02522-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/jac\/dkz267","volume":"74","author":"HI Bax","year":"2019","unstructured":"Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus. J Antimicrob Chemother. 2019;74:2930\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"1345_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-20","volume":"65","author":"BA Brown-Elliott","year":"2021","unstructured":"Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65:e01947-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR18","volume":"11","author":"GS Gill","year":"2019","unstructured":"Gill GS, Pulcini M. Maxillary osteomyelitis in a patient with pansinusitis and recently diagnosed focal segmental glomerulosclerosis. Cureus. 2019;11:e5347.","journal-title":"Cureus"},{"key":"1345_CR19","first-page":"1715","volume":"11","author":"T Morrisette","year":"2022","unstructured":"Morrisette T, Alosaimy S, Lagnf AM, et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative pathogens. Infect Dis Ther. 2022;11:1715\u201323.","journal-title":"Infect Dis Ther"},{"key":"1345_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002","volume":"8","author":"T Morrisette","year":"2021","unstructured":"Morrisette T, Alosaimy S, Philley JV, et al. Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections. Open Forum Infect Dis. 2021;8:ofab002.","journal-title":"Open Forum Infect Dis"},{"key":"1345_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00824-23","volume":"67","author":"A El Ghali","year":"2023","unstructured":"El Ghali A, Morrisette T, Alosaimy S, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023;67:e0082423.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad335","volume":"10","author":"CM Mingora","year":"2023","unstructured":"Mingora CM, Bullington W, Faasuamalie PE, et al. Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections. Open Forum Infect Dis. 2023;10:ofad335.","journal-title":"Open Forum Infect Dis"},{"key":"1345_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"1345_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380:425\u201336.","journal-title":"N Engl J Med"},{"key":"1345_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2337\/dc07-1744","volume":"31","author":"E Senneville","year":"2008","unstructured":"Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care. 2008;31:637\u201342.","journal-title":"Diabetes Care"},{"key":"1345_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.diagmicrobio.2013.12.007","volume":"78","author":"L Lauf","year":"2014","unstructured":"Lauf L, Ozsvar Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014;78:469\u201380.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1345_CR27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69:S16\u201322.","journal-title":"Clin Infect Dis"},{"key":"1345_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01703-21","volume":"66","author":"MJ Karau","year":"2022","unstructured":"Karau MJ, Schmidt-Malan SM, Cunningham SA, et al. Activity of omadacycline in rat methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother. 2022;66:e0170321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:e1\u201336.","journal-title":"Clin Infect Dis"},{"key":"1345_CR30","unstructured":"Oral omadacycline vs. placebo in adults with NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04922554. Accessed December 4, 2023."},{"key":"1345_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018426","volume":"98","author":"SH Lan","year":"2019","unstructured":"Lan SH, Chang SP, Lai CC, et al. The efficacy and safety of omadacycline in treatment of acute bacterial infection: a systemic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e18426.","journal-title":"Medicine (Baltimore)"},{"key":"1345_CR32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/jac\/dkad170","volume":"78","author":"AM Skinner","year":"2023","unstructured":"Skinner AM, Petrella LA, Cheknis A, Johnson S. Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials. J Antimicrob Chemother. 2023;78:1779\u201384.","journal-title":"J Antimicrob Chemother"},{"key":"1345_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/10600280221089007","volume":"57","author":"KW Garey","year":"2023","unstructured":"Garey KW, Rose W, Gunter K, et al. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Pharmacother. 2023;57:184\u201392.","journal-title":"Ann Pharmacother"},{"key":"1345_CR34","first-page":"952","volume":"29","author":"TP Lodise","year":"2023","unstructured":"Lodise TP, Gunter K, Mu F, et al. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. J Manag Care Spec Pharm. 2023;29:952\u201364.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01345-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:33Z","timestamp":1777484073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01345-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lucinda J. Van Anglen has received grant funding from Paratek Pharmaceuticals, Inc. Cathy L. Koo and Kimberly A. Couch declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The participating infusion centers are managed by a single organizational entity and share a centralized electronic medical record and data management system. As all data were maintained and accessed through this centralized system and no site-specific research activities were conducted, a single institutional review board approval covered all participating locations. The investigator and authors are authorized employees of this organizational entity and had organizational permission to access and analyze de-identified data for research purposes. The exempt study was conducted under our IRB approval from BRANY IRB #22\u201312-677\u20131297, and all data were handled in compliance with applicable privacy regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}